Intrinsic Capacity: How WHO's Healthy-Aging Measure Works Today, and Where Molecular Biomarkers Are Headed

The WHO defines Intrinsic Capacity by a person's physical and mental abilities, currently assessed via clinical and functional tests. Researchers are exploring molecular biomarkers, like epigenetic and inflammatory markers, to offer a more objective, quantitative measure of this capacity.

Maria Flores

October 20, 2026 · 5 min read

Intrinsic Capacity — the World Health Organization's term for the sum of a person's physical and mental abilities — is assessed today through clinical and functional tests, not blood work. But researchers are now probing whether molecular markers, especially epigenetic and inflammatory aging biomarkers, could one day offer a more objective, quantitative readout of the same underlying biology. A 2026 study published in JAMA Network Open by Rouch and colleagues found that accelerated epigenetic and inflammatory aging tracked with lower intrinsic capacity, hinting at a future in which a blood sample might flag functional decline before it becomes visible in a clinic. That future, however, remains firmly in the research phase.

Understanding Intrinsic Capacity: A WHO Concept

For decades, medicine measured aging largely by the diseases a person had accumulated. The WHO's concept of Intrinsic Capacity inverts that framing: instead of asking what is wrong with you, it asks what you can still do. Stanford neuroscientist Tony Wyss-Coray, whose lab studies biological aging, compares the concept to a molecular target. "Intrinsic capacity asks, What can you do, given your age? How fast can you walk? How much weight can you lift?" he explained in a Stanford Medicine explainer on biological versus chronological age. "It's really a reflection of how functional you are, given your age. And that's what we're trying to capture at a molecular level."

Wyss-Coray says he thinks of biological clocks as a way to capture someone's functional health in a more reproducible, quantitative way — the same goal the WHO pursues with its functional measure, which gauges cognition, mobility, energy and mood, among other factors. A review of recent advances in the field, published in PMC, frames Intrinsic Capacity as a reflection of an individual's biological aging process, and notes that its evaluation may provide an innovative mechanism for encouraging adults to adopt healthy lifestyles. Identifying biomarkers of capacity decline, that review adds, could offer simple and objective measurements of biological age and health status, and guide strategies to minimize decline — even delaying progress toward disability.

Clinical vs. Molecular: Two Approaches to Intrinsic Capacity Assessment

The clearest way to see where the field stands is to put the two approaches side by side. The table below contrasts the established clinical evaluation with the molecular research that aims to predict the same outcomes from biospecimens.

Established clinical assessment of Intrinsic Capacity versus emerging molecular biomarker research
Dimension	Clinical Assessment of Intrinsic Capacity	Molecular Biomarker Research for Intrinsic Capacity
Assessment type	Multi-domain clinical evaluations following WHO ICOPE guidelines, covering cognition, mobility, vitality, mood and sensory function	Exploratory analysis of biospecimens for molecular markers of biological aging
Examples of measures	Self-reported measures, physical measurements, cognitive tests such as the MMSE; research cohorts add DXA body-composition scans and whole-body/brain MRI	Epigenetic aging clocks and, to a lesser extent, inflammatory aging biomarkers
Purpose	Gauge an individual's functional health, identify decline, and encourage healthy lifestyles	Identify individuals at greater risk of functional decline earlier, and support precision-medicine interventions
Current status	Standard practice guided by WHO recommendations, though further validation studies are needed for pragmatic implementation	Research phase only; specific research on capacity biomarkers is rare, and validation is required before routine clinical use

The comparison makes the boundary explicit: the clinical column describes what a clinician can do today under WHO guidance, while the molecular column describes a goal, not a product. The two are complementary rather than competing — the JAMA study's own framing envisions combining biological age measurements with functional assessment to personalize interventions that extend health span.